Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics

Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on OnKure Therapeutics (OKUR – Research Report) and keeping the price target at $34.00.

Robert Burns has given his Buy rating due to a combination of factors related to OnKure Therapeutics’ promising developments. The company’s lead candidate, OKI-219, is a mutant-selective inhibitor currently in Phase 1 trials for solid tumors. Initial results have shown that the drug achieves steady-state exposure levels, providing near-continuous coverage for pAKT inhibition, which is crucial for its antitumor activity.
Furthermore, OKI-219 has demonstrated a favorable safety profile, with only mild treatment-related adverse events reported and no serious complications such as hyperglycemia. The absence of dose interruptions or reductions further supports the drug’s tolerability. The anticipation of updated trial results for OKI-219 as a monotherapy and in combination with FASLODEX in the second half of 2025 adds to the potential for positive outcomes, reinforcing the Buy rating.

In another report released on May 6, LifeSci Capital also maintained a Buy rating on the stock with a $20.00 price target.